Haifa, Israel

Gal Akiri

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2012-2014

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Gal Akiri: Innovator in Pharmaceutical Compositions

Introduction

Gal Akiri is a prominent inventor based in Haifa, Israel. He has made significant contributions to the field of pharmaceuticals, particularly in the area of cancer treatment. With a total of 3 patents to his name, Akiri's work focuses on innovative methods and compositions that aim to improve patient outcomes.

Latest Patents

Akiri's latest patents include groundbreaking pharmaceutical compositions and methods that are useful for modulating angiogenesis, inhibiting metastasis, and tumor fibrosis. One of his notable inventions provides methods and compositions suitable for modulating angiogenesis in mammalian tissue. Additionally, he has developed methods that are effective in inhibiting metastasis and fibrosis in mammalian tissue, as well as assessing the malignancy of colon cancer tumors.

Career Highlights

Gal Akiri is associated with the Technion Research & Development Foundation Limited, where he continues to advance his research and innovations. His work is characterized by a commitment to improving therapeutic strategies for cancer patients.

Collaborations

Throughout his career, Akiri has collaborated with esteemed colleagues such as Gera Neufeld and Zahava Vadasz. These partnerships have further enriched his research and contributed to the development of his patented technologies.

Conclusion

Gal Akiri stands out as an influential inventor in the pharmaceutical industry, with a focus on cancer treatment innovations. His contributions are paving the way for new therapeutic approaches that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…